HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time

AIDS

Volumn 20, Issue 2, 2006, Pages 159-170

  Ghosn, Jade ^a   Pellegrin, Isabelle ^b   Goujard, Cécile ^c   Deveau, Christiane ^c   Viard, Jean Paul ^a   Galimand, Julie ^a   Harzic, Martine ^d   Tamalet, Catherine ^e   Meyer, Laurence ^c   Rouzioux, Christine ^a   Chaix, Marie Laure ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HÔPITAL PELLEGRIN   (France)

^c INSERM   (France)

^d Le Chesnay Hospital   (France)

^e TIMONE HOSPITAL   (France)

Author keywords

Cellular reservoir; HIV DNA; HIV 1; Persistence; Primary infection; Resistance mutations

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSISTENT VIRUS INFECTION; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRION; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN; WESTERN BLOTTING;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENES, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MUTATION; PHYLOGENY; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 33646017725     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000199820.47703.a0     Document Type: Article

References (64)

1. Tamalet C, Fantini J, Tourres C, Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 2003; 17:2383-2388.
2. Richman D, Morton S, Wrin T, Hellmann N, Berry S, Shapiro M, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-1401.
3. Sabin CA, Hill T, Lampe F, Matthias R, Bhagani S, Gilson R, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ 2005; 330:695.
4. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-480.
5. Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 2000; 74:6262-6268.
6. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999; 73:3744-3752.
7. Yerly S, Jost S, Telenti A, Flepp M, Kaiser L, Chave JP, et al. Infrequent transmission of HIV-1 drug-resistant variants. Antiviral Ther 2004; 9:375-384.
8. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339:307-311.
9. Colson P, Ravaux I, Yahi N, Tourres C, Gallais H, Tamalet C. Transmission of HIV-1 variants resistant to the three classes of antiretroviral agents: implications for HIV therapy in primary infection. AIDS 2002; 16:507-509.
10. Taylor S, Cane P, Hue S, Xu L, Wrin T, Lie Y, et al. Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutations. AIDS Res Hum Retroviruses 2003; 19:353-361.
11. Descamps D, Chaix ML, Andre P, Brodard V, Cottalorda J, Deveau C, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005; 38:545-552.
12. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13:F123-F127.
13. Delaugerre C, Valantin MA, Mouroux M, Bonmarchand M, Carcelain G, Duvivier C, et al. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 2001; 15: 2189-2191.
14. Chan KC, Galli RA, Montaner JS, Harrigan PR. Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection. AIDS 2003; 17:1256-1258.
15. Little SJ, Koelsch KK, Ignacio CC, Wong JK, Frost SD, Richman D. Persistence of transmitted drug resistant virus among subjects with primary HIV infection deferring antiretroviral therapy. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 36LB].
16. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
17. Brenner B, Routy JP, Quan Y, Moisi D, Oliveira M, Turner D, et al. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 2004; 18:1653-1660.
18. Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18:1683-1689.
19. Harzic M, Pellegrin I, Deveau C, Chaix ML, Dubeaux B, Garrigue I, et al. Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment. AIDS 2002; 16:793-796.
20. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005; 365:1031-1038.
21. Bhaskaran K, Pillay D, Walker AS, Fisher M, Hawkins D, Gilson R, et al. Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters. AIDS 2004; 18:1471-1473.
22. Chaix ML, Descamps D, Harzic M, Schneider V, Deveau C, Tamalet C, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 2003; 17:2635-2643.
23. Schiffer V, Deveau C, Meyer L, Iraqui I, Nguyen-Wartel A, Chaix ML, et al. Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohort. HIV Medicine 2004; 5:326-333.
24. Desquilbet L, Goujard C, Rouzioux C, Sinet M, Deveau C, Chaix ML, et al. Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS 2004; 18:2361-2369.
25. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH. Médecine-Sciences Flammarion ed. Paris; 2004.
26. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH. Médecine-Sciences Flammarion ed. Paris; 1999.
27. Hoen B, Fournier I, Charreau I, Lacabaratz-Porret C, Burgard M, Arvieux C, et al. Structured treatment interruptions in primary HIV infection: final results of the multicenter prospective Primstop pilot trial. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 395].
28. Emilie D, Burgard M, Lascoux-Combe C, Laughlin M, Krzysiek R, Pignon C, et al. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS 2001; 15:1435-1437.
29. Goujard C, Marcellin F, Chavez H, Meiffredy V, Rouzioux C, Venet A, et al. HIV immune and virological responses following the administration of IL-2 either alone or combined to ALVAC-HIV 1433 and HIV lipopeptides in patients treated early with HAART during primary infection: the ANRS 095 randomized study. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 285].
30. Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 2005; 43:2709-2717.
31. Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, et al. Early Levels of HIV-1 DNA in Peripheral Blood Mononuclear Cells Are Predictive of Disease Progression Independently of HIV-1 RNA Levels and CD4+ T Cell Counts. J Infect Dis 2005; 192:46-55.
32. Kostrikis LG, Touloumi G, Karanicolas R, Pantazis N, Anastassopoulou C, Karafoulidou A, et al. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 2002; 76:10099-10108.
33. Pasquier C, Millot N, Njouom R, Sandres K, Cazabat M, Puel J, et al. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods 2001; 94:45-54.
34. Felsenstein J. PHYLIP, Phylogeny Inference Package, version 3.6 (alpha). In. Seattle: Department of genetics, University of Washington; 2001.
35. Sagar M, Lavreys L, Baeten JM, Richardson BA, Mandaliya K, Chohan BH, et al. Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol 2003; 77:12921-12926.
36. Delwart E, Magierowska M, Royz M, Foley B, Peddada L, Smith R, et al. Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS 2002; 16:189-195.
37. Palmer S, Kearney M, Maldarelli F, Kottilil S, Lucey D, Metcaf J, et al. Genetics of HIV-1 populations in acute and chronic infection. Antivir Ther 2002; 7:S43.
38. Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses 1998; 14: 869-876.
39. Strain MC, Gunthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh-Brown AJ, et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A 2003; 100:4819-4824.
40. Lambotte O, Chaix ML, Gubler B, Nasreddine N, Wallon C, Goujard C, et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 2004; 18:1147-1158.
41. Chun TW, Davey RT Jr, Ostrowski M, Shawn Justement J, Engel D, Mullins JI, et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 2000; 6:757-761.
42. Smith DM, Wong JK, Mai HT, Moreno JM, Russell TM, Ignacio CC, et al. Slow reversion of HIV transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in semen. Antivir Ther 2005; 10:S128.
43. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76:1753-1761.
44. Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, Bates M, et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003; 37:1693-1698.
45. Wirden M, Delaugerre C, Marcelin AG, Ktorza N, Ait Mohand H, Dominguez S, et al. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy. Antimicrob Agents Chemother 2004; 48:644-647.
46. Capetti AF, Gabris AI, Drago L, Vigevani GM. Can a K103N HIV strain stably overcome the wild type in the absence of non-nucleoside reverse transcriptase inhibitor selective pressure? AIDS 2005; 19:633-634.
47. Wei X, Liang C, Gotte M, Wainberg MA. Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis. Virology 2003; 311:202-212.
48. Turner D, Brenner B, Routy JP, Moisi D, Rosberger Z, Roger M, et al. Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr 2004; 37:1627-1631.
49. Delaugerre C, Morand-Joubert L, Chaix ML, Picard O, Marcelin AG, Schneider V, et al. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther 2004; 9:415-421.
50. Tang JW, Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol 2004; 30:1-10.
51. Chaix ML, Desquilbet L, Cottalorda J, Descamps D, Deveau C, Galimand J, et al. Sub-optimal response to HAART in patients treated at time of primary HIV-1 infection and infected with HIV resistant strains. Antivir Ther 2005; 10:S127.
52. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-188.
53. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000; 97: 3382-3387.
54. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-526.
55. Lacabaratz-Porret C, Urrutia A, Doisne JM, Goujard C, Deveau C, Dalod M, et al. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Infect Dis 2003; 187:748-757.
56. Samri A, Haas G, Duntze J, Bouley JM, Calvez V, Katlama C, et al. Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J Virol 2000; 74:9306-9312.
57. Samri A, Jeannin P, Marcelin AG, Costagliola D, Alatrakchi N, Biligui A, et al. CD8 T cell recognition of HIV-1 RT mutations induced by therapy with RT inhibitors in HIV-infected patients with persistent low viral load. Antivir Ther 2004; 9:S73.
58. Alatrakchi N, Duvivier C, Costagliola D, Samri A, Marcelin A, Kamkamidze G, et al. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS 2005; 19:25-33.
59. Ngo-Giang-Huong N, Candotti D, Goubar A, Autran B, Maynart M, Sicard D, et al. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res Hum Retroviruses 2001; 17: 1435-1446.
60. Katzenstein TL, Eugen-Olsen J, Hofmann B, Benfield T, Pedersen C, Iversen AK, et al. HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:10-14.
61. Madec Y, Boufassa F, Rouzioux C, Delfraissy JF, Meyer L. Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? Clin Infect Dis 2005; 40:1350-1354.
62. Hubert JB, Burgard M, Dussaix E, Tamalet C, Deveau C, Le Chenadec J, et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. AIDS 2000; 14:123-131.
63. Kantor R, Shafer RW, Follansbee S, Taylor J, Shilane D, Hurley L, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 2004; 18:1503-1511.
64. Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003; 187:683-686.